Singular Genomics Systems (OMIC) Q2 2024 earnings summary

Executive summary

• Advanced G4X Spatial Sequencer development, with early access targeted for late 2024 and commercial launch by end of Q2 2025, alongside the launch of spatial technology access services and expansion of the customer pipeline.

• Revenue is primarily from G4 instruments, consumables, and services, with a strategic pivot to spatial sequencing and multi-modal readouts.

• Workforce reduction of approximately 20% in March 2024 to focus resources on spatial sequencing, incurring $1.6 million in related expenses.

• Existing G4 customers are being supported and prepared for conversion to G4X, with system uptime averaging 95% in Q2.

• Reduced long-term lease obligations by $50 million through facility right-sizing.

Financial highlights

• Q2 2024 revenue was $0.7 million, with $0.4 million from consumables and $0.3 million from a capital instrument sale; revenue rose 46% year-over-year.

• Gross profit was negative $0.2 million, down from negative $0.1 million in Q2 2023, due to discounts, rental models, and higher support costs.

• Operating expenses were $22.6 million, down from $27.5 million in Q2 2023, reflecting lower headcount and absence of prior year one-time adjustments.

• Net loss was $21.3 million ($8.57/share), improved from $25.6 million ($10.58/share) in Q2 2023.

• Cash, cash equivalents, and short-term investments totaled $133.2 million at quarter end.

Outlook and guidance

• Early access for G4X planned for late Q4 2024, with commercial launch targeted for end of Q2 2025 and Direct-Seq release to follow.

• Q3 2024 cash burn expected to be higher due to a one-time $4.5 million lease modification payment.

• Cash runway guidance remains unchanged, extending to late 2026.

• Operating expenses expected to be slightly down near term but to increase longer term as G4X investments continue.

• Company anticipates continued significant losses and negative cash flows from operations for the foreseeable future.